Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen

Drug Development Research

Volumn 34, Issue 2, 1995, Pages 91-109

  Boyd, Michael R ^a   Paull, Kenneth D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

antineoplastics; cancer; drug development

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; ELLIPTICINE DERIVATIVE; HALOMON; SPONGISTATIN; UNCLASSIFIED DRUG;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG SCREENING; HUMAN; HUMAN CELL; INFORMATION PROCESSING; METHODOLOGY; REVIEW; TUMOR CELL;

EID: 0028906786     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.430340203     Document Type: Article

References (44)

1. Anticancer specificity of some ellipticinium salts against human brain tumors in vitro
2. Anticancer specificity of some ellipticinium salts against human brain tumors in vitro
3. Spongistatin 1, a highly cytotoxic, sponge‐derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin
4. National Cancer Institute drug discovery and development
5. Status of the NCI preclinical antitumor drug discovery screen
6. The future of new drug development
7. Data display and analysis strategies for the NCI disease‐oriented in vitro antitumor drug screen
8. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro
9. Searching for new molecular targets for therapy of cancer and AIDS: Characterization by 2D protein gel electrophoresis
10. Breast tumor cell lines from pleural effusions
11. Long‐term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
12. 31P magnetic resonance spectroscopy
13. Editorial: “Mean graphs” of NCI screening data
14. A pentahalogenated monoterpene from the red alga Portieria hornemannii, produces a novel cytotoxicity profile against a diverse panel of human tumor cell lines
15. Isolation and novel structure‐activity features of halomon‐related antitumor compounds from the red alga, Portieria hornemanii
16. Status of in vivo evaluations in the NCI anticancer drug discovery program
17. Two syngeneic cell lines from human breast tissue: The aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines
18. Exploratory data analytic techniques to evaluate anticancer agents screened in a cell culture panel
19. Establishment and characterization of a human prostatic carcinoma cell line (PC‐3)
20. Growth control of prostatic carcinoma cells in serum‐free media: Interrelationship of hormone response, cell density, and nutrient media
21. 2‐methylellipticinium acetate in human brain and non‐brain tumor cell lines
22. Establishment and characterization of a cell line of human breast carcinoma origin
23. Rhodamine efflux patterns predict PGP substrates in the NCI drug screen
24. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice
25. Feasibility of a high‐flux anticancer drug screen utilizing a diverse panel of human tumor cell lines in culture
26. Chromosomal analysis of human prostatic adenocarcinoma cell lines
27. Display and analysis of patterns of differential activity drugs against human tumor cell lines: Development of the mean graph and COMPARE algorithm
28. Identification of novel antimitotic agents acting at the tubulin level by computer‐assisted evaluation of differential cytotoxicity data
29. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute
30. Isolation and structure of spongistatin 1
31. Isolation and structure of the remarkable human cancer cell growth inhibitors spongistatins 2 and 3 from an Eastern Indian Ocean spongia sp
32. Isolation and structure of the powerful human cancer cell growth inhibitors spongistatins 4 and 5 from an African Spirastrella spinispirulifera (Porifera)
33. Antineoplastic agents 293: The exceptional human cancer cell growth inhibitors spongistatins 6 and 7
34. Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines
35. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker
36. New colorimetric cytotoxicity assay for anticancer drug screening
37. A human cell line from a pleural effusion derived from a breast carcinoma
38. Morphologic and immunocytochemical characteristics of human tumor cell lines for use in an anticancer drug screen
39. Isolation of a human prostate carcinoma cell line (DU 145)
40. Use of the Kohonen self‐organizing map to study the mechanisms of action of chemotherapeutic agents
41. Cellular uptake as a determinant of cytotoxicity of quaternized ellipticines to human brain tumor cells
42. Neural computing in cancer drug development: Predicting mechanism of action
43. Predictive statistics and artificial intelligence in the US National Cancer Institute's drug discovery program for cancer and AIDS